The prognosis of patients with myelodysplastic syndromes evolved in overt acute myeloid leukemia (MDS-AML) is generally very poor. With the standard anthracycline and cytosine arabinoside (AraC) combination currently employed in “de novo” AML, less than 50% of patients achieve complete remission (CR), with a median disease free survival (DFS) <= 10 months (Iw3). Since 1990’s, many efforts have been made to improve the outcome of this group of patients. According to the general statement concerning chemotherapy that “more is better”, an intensification with the addition of a third drug to standard induction treatment has been evaluated in several trials (4-6). In this study, we compare retrospectively patients with MDS-AML who...
Purpose Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplasti...
Item does not contain fulltextTwo main forms of therapy-related myelodysplastic syndrome and acute m...
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated inducti...
Item does not contain fulltextComparisons of the effectiveness of chemotherapy and transplantation i...
I term survival without an apparent effect on the initial re-sponse rate. However, reports of improv...
Purpose. To optimize treatment for younger patients with acute myeloid leukemia and high-risk myelod...
The outcome of treatment with standard first line therapy of 66 patients with acute myeloid leukaemi...
Disease staging and classification page 85 Cytogenetic abnormalities 87 Characteristics of MDS and a...
Intensive induction therapy-in acute myeloid leukemia (AML), as in some other systemic malignancies-...
Summary.-Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemo...
This aim of the acute myeloid leukaemia (AML)-R trial was to compare sequential (Seq) ADE (cytarabin...
Cytarabine and anthracycline combination therapy (7 + 3 regimen) is the standard care for induction ...
Introduction: Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination rema...
The treatment of acute myeloid leukemia (AML) has improved over the last two decades with better sup...
Treatment for a pre-existing condition using chemotherapy, radiation therapy, immunosuppressive ther...
Purpose Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplasti...
Item does not contain fulltextTwo main forms of therapy-related myelodysplastic syndrome and acute m...
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated inducti...
Item does not contain fulltextComparisons of the effectiveness of chemotherapy and transplantation i...
I term survival without an apparent effect on the initial re-sponse rate. However, reports of improv...
Purpose. To optimize treatment for younger patients with acute myeloid leukemia and high-risk myelod...
The outcome of treatment with standard first line therapy of 66 patients with acute myeloid leukaemi...
Disease staging and classification page 85 Cytogenetic abnormalities 87 Characteristics of MDS and a...
Intensive induction therapy-in acute myeloid leukemia (AML), as in some other systemic malignancies-...
Summary.-Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemo...
This aim of the acute myeloid leukaemia (AML)-R trial was to compare sequential (Seq) ADE (cytarabin...
Cytarabine and anthracycline combination therapy (7 + 3 regimen) is the standard care for induction ...
Introduction: Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination rema...
The treatment of acute myeloid leukemia (AML) has improved over the last two decades with better sup...
Treatment for a pre-existing condition using chemotherapy, radiation therapy, immunosuppressive ther...
Purpose Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplasti...
Item does not contain fulltextTwo main forms of therapy-related myelodysplastic syndrome and acute m...
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated inducti...